SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024
SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024
SI-BONE (NASDAQ: SIBN) is a global leader in technology for the surgical treatment of sacropelvic disorders. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 4,000 surgeons in performing more than 110,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including two randomized controlled trials and over 140 peer-reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.
加利福尼亚州圣克拉拉，2024年11月20日（全球新闻稿）——si-bone公司（纳斯达克：SIBN），是一家致力于解决骶髋疾病的医疗器械公司，今天宣布公司将参加即将在纽约举行的派杰投资医疗会议。管理层将在2024年12月4日星期三东部时间上午11:00 / 太平洋时间上午8:00举行一次炉边谈话。
Investors interested in listening to the conference call may do so by registering at this link: . Live audio of the webcast will be available on the "Investors" section of the company's website at: . The webcast will be archived and available for replay for at least 90 days after the event.
有兴趣收听电话会议的投资者可以通过此链接注册。网络直播的实时音频将在该公司网站的“投资者”版块上提供。网络直播将被存档并可在活动结束后至少90天内重播。
About SI-BONE, Inc.
SI-BONE, Inc.是全球领先的骶骨盆腔解剖学肌肉骨骼疾病外科治疗技术公司（NASDAQ:SIBN）。自2009年在SI关节的微创手术方面开创先河以来，SI-BONE支持超过3700名外科医生进行了超过100,000次的骶骨盆腔手术。一系列独特的临床证据支持SI-BONE的技术，包括四个随机对照试验和超过130篇同行评审出版物。SI-BONE利用其在微创椎盘融合方面的领导地位，推出了邻近市场的新解决方案，包括成人畸形，脊骨盆固定和盆腔创伤。
SI-BONE (NASDAQ: SIBN) is a global leader in technology for the surgical treatment of sacropelvic disorders. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 4,000 surgeons in performing more than 110,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including two randomized controlled trials and over 140 peer-reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.
si-bone（纳斯达克：SIBN）是全球领先的骶髋疾病外科治疗科技公司。自2009年首创si关节的微创手术以来，si-bone已支持超过4,000名外科医生进行超过110,000例骶髋手术。独特的临床证据支持si-bone技术的使用，包括两项随机对照试验和超过140篇经过同行评审的出版物。si-bone利用其在微创si关节融合方面的领导地位，开发出针对相邻市场的新颖解决方案，包括成人畸形、脊骨盆固定和骨盆创伤。
For additional information on the company or the products including risks and benefits, please visit .
iFuse Bedrock Granite，iFuse-TORQ，SI-BONE和iFuse INTRA是SI-BONE, Inc.的注册商标。 2024年SI-BONE，Inc.版权所有。
iFuse Bedrock Granite, iFuse-TORQ, iFuse TORQ TNT, SI-BONE, and iFuse INTRA are registered trademarks of SI-BONE, Inc. 2024 SI-BONE, Inc. All Rights Reserved.
iFuse Bedrock Granite、iFuse-TORQ、iFuse TORQ TNt、si-bone以及iFuse INTRA是si-bone公司的注册商标。2024 si-bone公司。保留所有权利。
Investor Contact: Saqib Iqbal investors@si-bone.com
投资者联系人：Saqib Iqbal investors@si-bone.com
